BioSight
Companies
NewAmsterdam Pharma Co N.V. logo

NAMS

NASDAQNARRDEN, P7
NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma develops obicetrapib, a drug candidate for cardiovascular disease, which it is testing both as a standalone treatment and in combination with ezetimibe. NewAmsterdam is in clinical development stage, working to obtain regulatory approval and establish physician adoption for obicetrapib. Success depends heavily on the efficacy and safety results from ongoing clinical trials and the company's ability to secure additional funding and compete in the cardiovascular market.

Price history not yet available for NAMS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar